Bulldock 025 SC

Primær information

  • Handelsnavn:
  • Bulldock 025 SC Suspensionskoncentrat
  • Lægemiddelform:
  • Suspensionskoncentrat
  • Sammensætning:
  • 25 g/l beta-cyfluthrin
  • Brugt til:
  • Planter
  • Medicin typen:
  • agrokemiske

Dokumenter

  • for den brede offentlighed:
  • Oplysningerne indlægssedlen for dette produkt er i øjeblikket ikke tilgængelig, kan du sende en anmodning til vores kundeservice, og vi vil give dig besked, så snart vi er i stand til at opnå det.


    Anmode informationsbrochure for offentligheden.

  • for sundhedspersonale:
  • Oplysningerne indlægssedlen for dette produkt er i øjeblikket ikke tilgængelig, kan du sende en anmodning til vores kundeservice, og vi vil give dig besked, så snart vi er i stand til at opnå det.


    Anmode informationsbrochure for sundhedspersonale.

Lokation

  • Fås i:
  • Bulldock 025 SC Suspensionskoncentrat
    Danmark
  • Sprog:
  • dansk

Andre oplysninger

Status

  • Kilde:
  • SEGES Landbrug & Fødevarer
  • Autorisation status:
  • Ikke længere markedsført
  • Autorisationsnummer:
  • 396-42
  • Sidste ændring:
  • 08-02-2018
  • Oplysningerne indlægssedlen for dette produkt er i øjeblikket ikke tilgængelig, kan du sende en anmodning til vores kundeservice, og vi vil give dig besked, så snart vi er i stand til at opnå det.

    Anmode informationsbrochure for offentligheden.

21-12-2017

Long-Acting Beta agonists (LABAs) and Inhaled Corticosteroids (ICS): Drug Safety Communication - Boxed Warning About Asthma-Related Death Removed

Long-Acting Beta agonists (LABAs) and Inhaled Corticosteroids (ICS): Drug Safety Communication - Boxed Warning About Asthma-Related Death Removed

FDA review of clinical safety trials shows that treating asthma with LABAs in combination with ICS does not result in significantly more serious asthma-related side effects than treatment with ICS alone.

FDA - U.S. Food and Drug Administration

20-12-2017

FDA Drug Safety Communication: FDA review finds no significant increase in risk of serious asthma outcomes with long-acting beta agonists (LABAs) used in combination with inhaled corticosteroids (ICS)

FDA Drug Safety Communication: FDA review finds no significant increase in risk of serious asthma outcomes with long-acting beta agonists (LABAs) used in combination with inhaled corticosteroids (ICS)

A U.S. Food and Drug Administration (FDA) review of four large clinical safety trials shows that treating asthma with long-acting beta agonists (LABAs) in combination with inhaled corticosteroids (ICS) does not result in significantly more serious asthma-related side effects than treatment with ICS alone. In 2011, we required the drug companies that market LABAs to conduct these trials to evaluate the safety of LABAs when used in combination with ICS, and we reviewed the results of these recently comple...

FDA - U.S. Food and Drug Administration

20-12-2017

FDA Drug Safety Communication: FDA requires post-market safety trials for Long-Acting Beta-Agonists (LABAs)

FDA Drug Safety Communication: FDA requires post-market safety trials for Long-Acting Beta-Agonists (LABAs)

[04-15-2011] To further evaluate the safety of Long-Acting Beta-Agonists (LABAs) when used in combination with inhaled corticosteroids for the treatment of asthma, the U.S. Food and Drug Administration (FDA) is requiring the manufacturers of LABAs to conduct five randomized, double-blind, controlled clinical trials comparing the addition of LABAs to inhaled corticosteroids versus inhaled corticosteroids alone.

FDA - U.S. Food and Drug Administration

6-4-2018

Beta-Blockers May Raise Mortality in People With Diabetes

Beta-Blockers May Raise Mortality in People With Diabetes

Use of beta-blockers may be associated with an increased mortality risk in patients with diabetes, particularly among those who have coronary heart disease (CHD), new research suggests.

US - RxList

6-4-2018

Beta-Blockers May Be Risky With Diabetes

Beta-Blockers May Be Risky With Diabetes

Beta-Blockers May Raise Mortality in People With Diabetes

US - eMedicineHealth

29-3-2018

Beta Blockers vs. Valium

Beta Blockers vs. Valium

Title: Beta Blockers vs. ValiumCategory: MedicationsCreated: 3/29/2018 12:00:00 AMLast Editorial Review: 3/29/2018 12:00:00 AM

US - MedicineNet

28-3-2018

EU/3/17/1876 (FGK Representative Service GmbH)

EU/3/17/1876 (FGK Representative Service GmbH)

EU/3/17/1876 (Active substance: Sodium (1R,3R,4R,5S)-3-({2-N-acetylamino-2-deoxy-3-O-[(1S)-1-carboxylato-2-cyclohexylethyl]-beta-D-galactopyranosyl}oxy)-4-({6-deoxy-alpha-L-galactopyranosyl}oxy)-5-ethyl-cyclohexan-1-yl-(38-oxo-2,5,8,11,14,17,20,23,26,29,32,35-dodecaoxa-39-azahentetracontan-41-yl)carboxamide) - Transfer of orphan designation - Commission Decision (2018)2011 of Wed, 28 Mar 2018 European Medicines Agency (EMA) procedure number: EMA/OD/010/17/T/01

Europe -DG Health and Food Safety

21-3-2018

Beta Blockers vs. Calcium Channel Blockers

Beta Blockers vs. Calcium Channel Blockers

Title: Beta Blockers vs. Calcium Channel BlockersCategory: MedicationsCreated: 3/21/2018 12:00:00 AMLast Editorial Review: 3/21/2018 12:00:00 AM

US - MedicineNet

21-3-2018

Beta Blockers vs. ARBs

Beta Blockers vs. ARBs

Title: Beta Blockers vs. ARBsCategory: MedicationsCreated: 3/21/2018 12:00:00 AMLast Editorial Review: 3/21/2018 12:00:00 AM

US - MedicineNet

20-3-2018

Mircera (Roche Registration GmbH)

Mircera (Roche Registration GmbH)

Mircera (Active substance: methoxy polyethylene glycol-epoetin beta) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)1741 of Tue, 20 Mar 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/739/T/66

Europe -DG Health and Food Safety

19-3-2018

NeoRecormon (Roche Registration GmbH)

NeoRecormon (Roche Registration GmbH)

NeoRecormon (Active substance: Epoetin beta) - Centralised - Transfer Marketing Authorisation Holder - Commission Decision (2018)1693 of Mon, 19 Mar 2018 European Medicines Agency (EMA) procedure number: EMEA/H/C/116/T/98

Europe -DG Health and Food Safety

12-3-2018

Topamax vs. Propranolol

Topamax vs. Propranolol

Topamax (topiramate) and propranolol are used to prevent migraine headaches. Topamax is also used to prevent epileptic seizures. Propranolol is also used to treat tremors, angina (chest pain), hypertension (high blood pressure), heart rhythm disorders, and other heart or circulatory conditions. Topamax and propranolol belong to different drug classes. Topamax is an anticonvulsant and propranolol is a beta-blocker.

US - RxList

20-2-2018

Flagyl vs. Zosyn

Flagyl vs. Zosyn

Flagyl, Flagyl ER, and Flagyl Injection (metronidazole) and Zosyn (piperacillin and tazobactam for injection) are antibiotics used to treat bacterial infections. Flagyl and Zosyn are different types of antibiotics. Flagyl is a nitroimidazole antibiotic and Zosyn is a combination of a penicillin-class antibacterial and a beta-lactamase inhibitor.

US - RxList

1-2-2018

Cozaar vs. Atenolol

Cozaar vs. Atenolol

Cozaar (losartan) and atenolol are used to treat hypertension. Atenolol is also used to treat chest pain (angina), for management of acute heart attack (myocardial infarction), and occasionally for thyroid storm management. Cozaar and atenolol belong to different drug classes. Cozaar is an angiotensin receptor blocker (ARB) and atenolol is a beta-blocker.

US - RxList

19-1-2018

EU/3/17/1969 (University of Cambridge)

EU/3/17/1969 (University of Cambridge)

EU/3/17/1969 (Active substance: Recombinant adeno-associated viral vector serotype 2/1 encoding human beta-hexosaminidase alpha and beta subunits) - Orphan designation - Commission Decision (2018)391 of Fri, 19 Jan 2018 European Medicines Agency (EMA) procedure number: EMA/OD/182/17

Europe -DG Health and Food Safety

19-1-2018

BETA MANGOSTIN Powder [Office Of Academy And Industry Collaboration GNU]

BETA MANGOSTIN Powder [Office Of Academy And Industry Collaboration GNU]

Updated Date: Jan 19, 2018 EST

US - DailyMed

29-12-2017

EXTAVIA (Interferon Beta-1b) Kit [Novartis Pharmaceuticals Corporation]

EXTAVIA (Interferon Beta-1b) Kit [Novartis Pharmaceuticals Corporation]

Updated Date: Dec 29, 2017 EST

US - DailyMed

22-12-2017

Fabrazyme (Genzyme Europe B.V.)

Fabrazyme (Genzyme Europe B.V.)

Fabrazyme (Active substance: Agalsidase beta) - Centralised - Yearly update - Commission Decision (2017)9088 of Fri, 22 Dec 2017

Europe -DG Health and Food Safety

30-11-2017

Coreg vs. Lopressor

Coreg vs. Lopressor

Coreg (carvedilol) and Lopressor (metoprolol tartrate) are beta-adrenergic blocking agents (beta-blockers) used to treat heart failure, hypertension, and heart attacks. Lopressor is also used to treat angina.

US - RxList

16-11-2017

ALBUTEROL SULFATE Solution [Nephron SC Inc.]

ALBUTEROL SULFATE Solution [Nephron SC Inc.]

Updated Date: Nov 16, 2017 EST

US - DailyMed

16-11-2017

IPRATROPIUM BROMIDE AND ALBUTEROL SULFATE Solution [Nephron SC Inc.]

IPRATROPIUM BROMIDE AND ALBUTEROL SULFATE Solution [Nephron SC Inc.]

Updated Date: Nov 16, 2017 EST

US - DailyMed

16-11-2017

IPRATROPIUM BROMIDE Solution [Nephron SC Inc.]

IPRATROPIUM BROMIDE Solution [Nephron SC Inc.]

Updated Date: Nov 16, 2017 EST

US - DailyMed

14-11-2017

Plegridy (Biogen Idec Limited)

Plegridy (Biogen Idec Limited)

Plegridy (Active substance: peginterferon beta-1a) - PSUSA - Modification - Commission Decision (2017)7618 of Tue, 14 Nov 2017 European Medicines Agency (EMA) procedure number: EMEA/H/C/PSUSA/10275/201701

Europe -DG Health and Food Safety

14-11-2017

BETA 1 KIT (Betamethasone Sodium Phosphate, Betamethasone Acetate) Kit [Oaklock, LLC]

BETA 1 KIT (Betamethasone Sodium Phosphate, Betamethasone Acetate) Kit [Oaklock, LLC]

Updated Date: Nov 14, 2017 EST

US - DailyMed

25-10-2017

Calcium Chloride

Calcium Chloride

Calcium Chloride is a mineral indicated in the immediate treatment of hypocalcemic tetany (abnormally low levels of calcium in the body that cause muscle spasm). Calcium chloride injection is also used in cardiac resuscitation, arrhythmias, hypermagnesemia, calcium channel blocker overdose, and beta-blocker overdose.

US - RxList